TrialThe British journal of dermatology2020

Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1).

K Papp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.